PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for Angiomax® (bivalirudin) in support of a proposed new dosage for immediate treatment of patients with acute coronary syndromes (ACS). Angiomax is currently approved for patients undergoing percutaneous coronary intervention (PCI), commonly referred to as angioplasty.
